Scarica l'app Stockscreener
46.43
6.28%
2.62
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Momentum Shift: Will Oruka Therapeutics Inc benefit from AI trendsQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD - Investing.com
Aug Selloffs: Will Oruka Therapeutics Inc outperform tech stocksQuarterly Investment Review & AI Powered Market Entry Strategies - baoquankhu1.vn
Does Oruka’s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)? - Yahoo Finance Singapore
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US6876041087 - marketscreener.com
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | HQ1 | US6876041087 - marketscreener.com
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighStill a Buy? - MarketBeat
Does Oruka Therapeutics, Inc. (ORKA) have the potential to rally 41.51% as Wall Street analysts expect? - MSN
BTIG Reiterates Oruka Therapeutics (ORKA) Buy Recommendation - MSN
Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock By Investing.com - Investing.com India
Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $16,313.50 in Stock - MarketBeat
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,641 Shares of Stock - MarketBeat
Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $71,407.70 in Stock - MarketBeat
Agarwal Arjun, Oruka Therapeutics SVP, sells $16k in ORKA stock - Investing.com Canada
[Form 4] Oruka Therapeutics, Inc. Insider Trading Activity - Stock Titan
Does Oruka Therapeutics, Inc. (ORKA) Have a Chance to Surge 41.51% According to Wall Street Analysts’ Predictions? - Bitget
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect? - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $86.00 at Leerink Partners - Defense World
Is Oruka Therapeutics’ (ORKA) ESOP Shelf Registration Quietly Redefining Its Funding Playbook? - simplywall.st
Oruka Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Oruka Therapeutics, Inc. $ORKA is Fairmount Funds Management LLC's 7th Largest Position - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Raised to Hold at Wall Street Zen - MarketBeat
Commodore Capital LP Has $33.71 Million Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Braidwell LP Sells 142,492 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
BTIG Research Reaffirms “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Wedbush Reaffirms Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Oruka Therapeutics stock hits 52-week high at 36.53 USD By Investing.com - Investing.com India
Avoro Capital Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Barclays Raises Price Target for ORKA to $50, Maintains Overweig - GuruFocus
ORKA’s Recent Moves Signal Strategic Realignment Amid Market Shifts - timothysykes.com
Barclays Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $72.00 - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Given "Buy" Rating at BTIG Research - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week High on Strong Earnings - MarketBeat
Oruka Therapeutics stock hits 52-week high at 36.53 USD - Investing.com
BTIG reiterates Buy on Oruka Therapeutics stock, $73 target - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Receives "Outperform" Rating from Wedbush - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Earns "Buy" Rating from Guggenheim - MarketBeat
Assessing Oruka Therapeutics (ORKA) Valuation As ORKA-001 Moves Into Long Term Psoriasis Trial - Sahm
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Oruka Therapeutics (NASDAQ:ORKA) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
Oruka psoriasis drug targets twice-yearly dosing in Phase 2 trials - Stock Titan
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 7.8%Time to Sell? - MarketBeat
Should Oruka’s Once-Yearly ORKA-001 Psoriasis Dosing Ambition Require Action From Oruka Therapeutics (ORKA) Investors? - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Piper Sandler initiates coverage of Oruka Therapeutics (ORKA) with overweight recommendation - MSN
Published on: 2026-03-08 05:39:15 - baoquankhu1.vn
Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market - TipRanks
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):